Search

Introduction: Despite the available secondary preventive treatments, the management of stable coronary artery disease (SCAD) remains challenging. Intermediate coronary lesion (ICL), defined as luminal stenosis between 50% and 70%, is a key stage of SCAD. However, existing therapeutic strategies are limitated in delaying plaque progression and associated with various adverse effects and economic burdens. Qing-Xin-Jie-Yu Granules (QXJYG) with proven anti-platelet, anti-inflammatory, and lipid-lowering effects may compensate for the drawbacks of current treatments and can be tested as a complementary therapy. Therefore, this study aims to investigate the efficacy and safety of QXJYG in treating ICL, with a particular focus on its impact on myocardial ischemia and plaque progression. Materials and methods: This is a multicenter, randomized, double-blind, placebo-controlled trial. A total of 120 participants with ICL will be randomly assigned to two groups in a 1:1 ratio. In addition to basic medications, the intervention group will receive QXJYG, while the control group will receive a placebo for over 6 months, followed by a 12-month follow-up. The primary efficacy outcome is computed tomography-derived fractional flow reserve. The secondary outcomes include the degree of coronary stenosis, coronary artery calcification score, Gensini score, Seattle Angina Questionnaire score, high-sensitivity C-reactive protein, matrix metalloproteinase-9, blood lipids, and carotid artery ultrasound parameters. Major adverse cardiovascular events are recorded as endpoints. The safety outcomes include composite events of bleeding, laboratory test results, and adverse events. Clinical visits are scheduled at baseline, every 2 months during the treatment, and after a 12-month follow-up. Discussion: This trial is anticipated to yield reliable results to verify the efficacy and safety of QXJYG in the treatment of ICL, which will provide novel insights to help address the prevailing therapeutic dilemma of ICL, thereby facilitating for the management of SCAD. Trial registration: Chinese Clinical Trial Registry, ChiCTR2200059262. Registered on April 27, 2022. [ABSTRACT FROM AUTHOR]

Single-walled carbon nanotubes (SWCNTs) loaded with magnetic iron oxide nanoparticles were prepared by the arc discharge method and air heat treatment. The nanocomposite was characterized by X-ray diffraction, scanning electron microscopy, Raman spectroscopy, vibrating sample magnetometry, etc. The results showed that the heat-treated nanocomposites (SWCNTs/FexOy) had iron oxide phases and superparamagnetic properties with a saturation magnetization of 33.32 emu/g. Compared with the non-heat-treated materials, SWCNTs/FexOy had a larger specific surface area and pore volume. Using SWCNTs/FexOy to remove the organic contaminant (bisphenol A, BPA), it was found that under the conditions of pH = 3 and adsorbent dosage of 0.2 g/L, the maximum adsorption capacity of the composite was 117 mg/g, and the adsorption could reach more than 90% in only 5 min when the BPA content was below 0.05 mmol/L. The fitting results of the Langmuir and D-R models are more consistent with the experimental data, indicating a relatively uniform distribution of the adsorption sites and that the adsorption process is more consistent with physical adsorption. The kinetic calculations showed that the SWCNTs/FexOy exhibits chemical effects on both the surface and the gap, and the adsorption process is controlled by the π-π bonds and the hydrophobicity of the SWCNTs/FexOy. [ABSTRACT FROM AUTHOR]